

Published in "Antimicrobial Agents and Chemotherapy doi: 10.1128/AAC.00278-18, 2018"  
which should be cited to refer to this work.

1           **Genetic and functional characterization of an MCR-3-like producing**

2                           *Escherichia coli* recovered from swine, Brazil

3           **Nicolas Kieffer,<sup>1,2</sup> Patrice Nordmann,<sup>1,2,3,4</sup> Andrea Micke Moreno,<sup>5</sup> Luisa Zanolli**

4           **Moreno,<sup>5</sup> Richard Chaby,<sup>6</sup> Aude Breton,<sup>6</sup> Pierre Tissières,<sup>6</sup> and Laurent Poirel<sup>1,2,4\*</sup>**

5           <sup>1</sup>Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science,  
6           University of Fribourg, Fribourg, Switzerland, <sup>2</sup>INSERM European Unit (IAME, France),  
7           University of Fribourg, Fribourg, Switzerland, <sup>3</sup>Institute for Microbiology, University of  
8           Lausanne and University Hospital Centre, Lausanne, Switzerland, <sup>4</sup>Swiss National Reference  
9           Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Switzerland  
10          <sup>5</sup>Departamento de Medicina Veterinária Preventiva e Saúde Animal, Faculdade de Medicina  
11          Veterinária e Zootecnia, São Paulo, Brazil, and <sup>6</sup>Institute for integrative biology of the cell  
12          (I2BC), CEA, CNRS, Université Paris-Sud, Université Paris-Saclay, Orsay, France

13

14          Running title: Characterization of MCR-3.12

15          Keywords ; polymyxin, plasmid, *mcr*

16

17

18          \*Corresponding author. Mailing address: Medical and Molecular Microbiology  
19          Unit, Department of Medicine, Faculty of Science, University of Fribourg, Chemin du  
20          Musée 18, CH-1700 Fribourg, Switzerland. Phone: 41-26-300-9582. E-mail:  
21          [laurent.poirel@unifr.ch](mailto:laurent.poirel@unifr.ch)

22

<http://doc.rero.ch>

23

24 A collection of 126 pigs were screened for carriage of colistin-resistant  
25 Enterobacteriaceae in a farm in Minas Gerais, Brazil. Out of this collection, eighth  
26 colistin-resistant *Escherichia coli* isolates were recovered, including one from Minas  
27 Gerais State, producing a new MCR-3 variant (MCR-3.12). Analysis of the  
28 lipopolysaccharide revealed that MCR-3.12 had a similar function as MCR-1 and MCR-  
29 2 by adding a phosphoethanolamine group to the lipid A. Genetic analysis showed that  
30 the *mcr-3.12* gene was carried by an IncA/C<sub>2</sub> plasmid and was embedded in an original  
31 genetic environment. This study reports the occurrence of the MCR-3-like determinant  
32 in South America and firstly demonstrates the functionality of this group of enzymes as  
33 a phosphoethanolamine transferase.

34

35

36

## INTRODUCTION

37 The increasing occurrence of colistin-resistant Enterobacteriaceae is of great concern since  
38 colistin represents one of the last-resort treatments for infections caused by carbapenem-  
39 resistant Enterobacteriaceae (CRE). In addition to chromosomally-encoded resistance  
40 mechanisms corresponding to mutations or deletions in genes involved in the biosynthesis of  
41 the lipopolysaccharide (LPS), acquired resistance through horizontal gene transfer has been  
42 recently described (1). Five different plasmid-mediated colistin resistance genes have been  
43 identified so far in Enterobacteriaceae, including *mcr-1*, *mcr-2*, *mcr-3*, *mcr-4* and *mcr-5* (2-6).  
44 They code for enzymes that modify the lipid A moiety of the LPS of Gram-negative bacteria  
45 and consequently conferring resistance to polymyxin B and colistin (1). To date, only MCR-1  
46 and MCR-2 have been shown to function as phosphoethanolamine transferases (7). The *mcr-1*  
47 and *mcr-2* genes likely originate from *Moraxella* species (8), with *Moraxella pluranimalium*  
48 being the progenitor of *mcr-2* (9), *Aeromonas* spp. that of *mcr-3*-like genes (4), and  
49 *Shewanella* spp. that of *mcr-4*-like genes (5). The origin of the newly discovered *mcr-5* gene  
50 remains unknown (6). The high prevalence of MCR-1-producing *E. coli* isolates in food-  
51 producing animals, and therefore the high rate of colistin-resistant isolates may be explained  
52 by the constant use of colistin in veterinary medicine, in particular in livestock for the

53 treatment of poultry, swine and cattle (1). To date, six *mcr-3* variants have been reported since  
54 the discovery of *mcr-3.1* in June 2017, identified from an *Echerichia coli* isolate from a  
55 healthy pig in China (4) and in a *Salmonella* isolate from human infections in Denmark (10).  
56 The *mcr-3.2* variant was identified in *E. coli* from cattle in Spain (11). The *mcr-3.3* to -3.9  
57 variants were identified in *Aeromonas* spp. (12-15), and the *mcr-3.10* in *E. coli* from duck in  
58 China (15). Finally, the *mcr-3.11* gene was from an *E. coli* isolate recovered from chicken in  
59 China (unpublished, Genbank accession number MG489958.1). Even if *Aeromonas* spp. was  
60 described as the progenitor of the *mcr-3* genes, this gene might also be found as an acquired  
61 determinant in that species (13).  
62 Here we report a novel *mcr-3* variant detected in an *E. coli* isolate recovered from a post-  
63 weaning diarrhea of a pig that was previously treated by colistin in Brazil.

## 64 RESULTS

65 **Characterization of a new *mcr-3* variant and susceptibility testing.** Out of the 126  
66 pig samples, eight samples were found to contain colistin-resistant *E. coli* isolates. All the  
67 animals received treatment including colistin for 15 days after the weaning period. Out of the  
68 8 colistin-resistant *E. coli* isolates, only a single isolate (I112) was positive by PCR for the  
69 *mcr-3* gene. The other colistin-resistant *E. coli* isolates remaining negative for the other *mcr-*

70 like genes. Sequencing of the PCR products revealed that the *mcr-3*-like gene corresponded to  
71 a new variant named *mcr-3.12* (Genbank accession number: MG564491) encoding for a  
72 MCR-3.12 enzyme sharing 97% of amino-acid identity with the original MCR-3 variant and  
73 between 97% and 99% of amino-acid identity with the other MCR-3-like variants (Figure 1).  
74 Isolate I112 showed resistance to broad-spectrum cephalosporins, tetracycline,  
75 chloramphenicol, florfenicol, nalidixic acid, sulfonamides, sulfomethoxazole/trimethoprim  
76 and kanamycin. It was found positive with the Rapid Polymyxin NP test and showed an MIC  
77 of colistin at 4 µg/ml using broth microdilution method. MLST analysis showed that isolate  
78 I112 belonged to the ST641 and to the phylogroup A. Analysis with Serotypefinder1.1  
79 indicated that it belonged to the O160:H25 serotype. Phylogenetic analysis of the known *mcr-*  
80 *3* showed a significant diversity among the variants. Three major subgroups could be  
81 identified including, (i) MCR-3.5, MCR-3.6 and MCR-3.8, (ii) MCR-3.4 and the MCR-3.11,  
82 (iii) MCR-3.1, MCR-3.2, MCR-3.3, MCR-3.7 and MCR-3.11, respectively. The MCR-3.9  
83 and MCR-3.10 enzymes were found to be both close to MCR-3.12 and MCR-3.1 variants  
84 (Figure 1).

85 **MCR-3 is a phosphoethanolamine transferase conferring resistance to colistin.**

86 Mass spectrometry analysis of the LPS showed that unlike the J53 negative control showing a

87 single  $m/z$  1798 peak corresponding to the bis-phosphorylated hexa acylated lipid A, the  
88 MCR-1 and MCR-3 producers showed an identical additional peak at  $m/z$  1921 ( $\Delta m/z$  123)  
89 corresponding to an addition of a phosphoethanolamine (PEtN) groupment to the lipid A as it  
90 was previously described (7, 16) (Figure 2). Induction of the pBAD<sub>b</sub>-*mcr-3-like* plasmid  
91 allowed to obtain an MIC of colistin at 4  $\mu\text{g/ml}$  whereas the non-induced clone presented an  
92 MIC at 0.03  $\mu\text{g/ml}$  showing that the production of MCR-3-12 conferred a 130-fold increase of  
93 colistin MIC. Altogether, these results showed the phosphoethanolamine transferase activity  
94 of the MCR-3.12 enzyme and its impact on the colistin susceptibility.

95 **Plasmid analysis.** Mating-out assays were successful with *E. coli* J53 and *Klebsiella*  
96 *pneumoniae* CIP53153 as recipients, but also with *Aeromonas punctata* CIP102629,  
97 highlighting its broad host range property. By contrast, no transconjugant was obtained using  
98 *P. aeruginosa* PaO1 as recipient. Conjugation followed by PCR showed that *mcr-3.12* was  
99 located onto a conjugative plasmid named p112. That latter plasmid encoded resistance to  
100 tetracyclines, sulfonamides, chloramphenicol and florfenicol. PBRT analysis showed that  
101 plasmid p112 belonged to the IncA/C<sub>2</sub> incompatibility group. Kieser extraction followed by  
102 gel electrophoresis identified its size to be ca. 140-kb in size. MICs of colistin of the *E. coli*  
103 and *K. pneumoniae* transconjugants were at 4 and 8  $\mu\text{g/ml}$ , respectively, being therefore

104 categorized as resistant according to the EUCAST breakpoint (original MICs of the bacterial  
105 hosts being at 0.25 and 0.12 µg/ml, respectively) (<http://www.eucast.org>). Interestingly, MICs  
106 of colistin of the *A. punctata* transconjugant was at 16 µg/ml (original MIC at 0.12 µg/ml),  
107 indicating a very significant impact of MCR-3.12 on colistin susceptibility in that species.

108 **Bioinformatic analysis and genetic context of the *mcr-3-12* gene.** Whole genome  
109 sequencing of *E. coli* I112 data identified a series of resistance determinants including genes  
110 encoding resistance to β-lactams (*bla*<sub>TEM-1B</sub> and *bla*<sub>CTX-M-8</sub> genes), aminoglycosides (*aph*[3']-  
111 *Ia*, *strA* and *strB*), tetracyclines (*tetA*), phenicols (*catA1* and *floR*), sulphonamides (*sul2*) and  
112 trimethoprim (*dhfr18*). The *mcr-3*-like gene was found in association with a gene encoding for  
113 a diacylglycerol kinase *dgkA*-like sharing 98% of nucleotide identity with the *dgkA* gene  
114 identified in association with the first *mcr-3* described on plasmid pWJ1 (4).

115 The *mcr-3.12* gene was located between two insertion sequences belonging to the IS66  
116 and IS30 families, respectively (Figure 3). Interestingly, 90-bp after the end of the inverted  
117 repeat right (IRR) of the IS30-like, an IRL-like of the IS66 was detected, sharing 100% of  
118 nucleotide identity with the first 24-nt of the IRL of IS66 (Figure 3). The presence of this  
119 IRL-like downstream the IS30-like could form a putative transposon with the IS66.

120 Further analysis showed that this putative transposon was embedded in a longer structure that  
121 was inserted between nucleotides 1,049 and 1,050 of a DNA methyltransferase gene located  
122 on the IncA/C<sub>2</sub> backbone. This structure was 20,376-bp long and is represented in Figure 3F.  
123 It could be defined into three different regions, (i) a 5' region characterized by a 7,666-bp  
124 region with a GC content of 39% containing three putative open reading frames including two  
125 encoding for putative site-specific integrases, (ii) the putative transposon containing the *mcr-3*  
126 variant and three ORFs ( $\alpha$ ,  $\beta$  and  $\gamma$ ) presenting a GC content of 49% and (iii) a 3' region of  
127 526-bp with a similar %GC as the first 7,666-bp region (Figure 3F). The ORF  $\alpha$ ,  $\beta$  and  $\gamma$   
128 encoded for a reverse transcriptase, a transcriptional regulator and a diguanylate cyclase,  
129 respectively. Their products showed strong amino acid identity (98%) with putative proteins  
130 from *Aeromonas dhakensis*.

## 131 DISCUSSION

132 We report here the identification of a novel variant of the *mcr-3* gene, detected in an *E.*  
133 *coli* isolate recovered from a pig in Brazil. Interestingly, previous studies also described  
134 MCR-3 producers recovered from animal samples (11, 13), suggesting the same link between  
135 animal and colistin resistance as it has been established for the *mcr-1* gene. The pigs screened  
136 in this study were treated previously with colistin for fifteen days after the weaning period.



137 This suggests the possible selection of colistin-resistant strain during this period as we showed  
138 in our previous study describing a high prevalence of MCR-1-producers in a pig farm in  
139 Portugal where animals had received colistin (17). There have been many reports of MCR  
140 producers in Brazil, with MCR-1 being the only variant systematically identified. These  
141 isolates were a single *Salmonella enterica* serotype Typhimurium was recovered from retail  
142 meat (18), *E. coli* isolates recovered from chicken meat (19), from migratory penguins (20),  
143 recovered on public beaches (21), or recovered from patients with bloodstream infections (22,  
144 23). Also, KPC-2-producing *E. coli* (24), and KPC-2-producing *Klebsiella pneumoniae*  
145 belonging to ST392 and ST437 (25, 26) were identified. A quite extensive study identified a  
146 series of 59 MCR-1-producing *E. coli* isolates recovered from humans, chicken, chicken  
147 meat, bovine, turkey, swine and penguin (27). However, we might speculate that most studies  
148 were designed to detect only the *mcr-1* gene so far, and few investigating the occurrence of  
149 the most recently-identified other variants.

150 Isolate I112 carried a novel *mcr-3* variant named *mcr-3.12*. It belonged to ST641  
151 which was previously found to carry the *mcr-1* gene, corresponding to isolates recovered from  
152 pigs in Germany in 2016 (28). It belongs to the phylogroup A of *E. coli* therefore  
153 corresponding to a commensal strain. Sequence alignment analysis showed that *mcr-3.12*

154 shares 99% of nucleotide identity with a sequence from *Aeromonas veronii*. This suggests that  
155 this new variant may have originated from that particular species or may have widely  
156 disseminated as an acquired resistance trait within that species. Noteworthy, we showed here  
157 that the IncA/C<sub>2</sub>-type plasmid bearing the *mcr-3.12* gene could replicate in *Aeromonas* sp. We  
158 may therefore speculate that such plasmid type might have been involved in the original  
159 spread of *mcr-3*-like genes from their progenitors to other bacterial species, including  
160 members of the *Enterobacteriaceae* family.

161 Induction experiments and analysis of the lipid A of the isolate strongly indicates that  
162 the MCR-3 enzyme confers colistin resistance the same way as MCR-1 and MCR-2 enzymes  
163 by adding a phosphoethanolamine group to the lipid A although this enzyme only shared 45  
164 and 47% of amino-acid identity with MCR-1 and MCR-2, respectively. The fact that MCR-1,  
165 -2, and -3 share similar functions was previously hypothesized through an in-silico protein  
166 structure analysis (4).

167 The *mcr-3* gene was previously described onto IncHI2 and IncX4 plasmids which are  
168 commonly found in association with the *mcr-1* and *mcr-2* genes. Here, we described the first  
169 IncA/C<sub>2</sub> plasmid carrying a plasmid-mediated colistin resistance determinant. This plasmid  
170 backbone is commonly identified as a support of many different antibiotic resistance genes.

171 Here, the determinants *tetA*, *sul2* and *floR* encoding for resistance to tetracycline,  
172 sulfonamides and phenicols respectively, were also detected on this same plasmid. The broad  
173 host range of this plasmid was demonstrated, by evidencing its ability to replicate not only in  
174 *E. coli* and *K. pneumoniae*, but also in *A. punctata*.

175 The *mcr-3.12* is located into a putative transposon including the *IS66* upstream of the  
176 *mcr-3* gene and an *IS30-like* downstream. Interestingly, a 24-nt region found 90-bp  
177 downstream the *IS30-like* was found identical to the IRL of the *IS66*. Further experiments will  
178 be conducted to confirm whether *IS66* could have played a role in the acquisition of this  
179 phosphoethanolamine transferase gene by a mechanism similar to a one-handed transposition  
180 as it has been described for *ISEcp1* in the mobilization of *bla<sub>CTX-M-15</sub>* (29).

181 The genetic context of the putative *mcr-3* transposon is complex and the chronology of  
182 acquisition of this structure into the *IncA/C2* plasmid can hardly be explained. One hypothesis  
183 is summarized in the Figure 3. The *IS66* might have been involved in the original  
184 mobilization of the *mcr-3.12* gene from *Aeromonas* spp. (Figures 3A-D). Then, a second  
185 mobilization event may have occurred involving an unknown mechanism between the genetic  
186 structure containing the putative integrases (Figure 3E) and the *mcr-3*-carrying structure  
187 forming an 20,376-bp integron-like genetic complex. Finally, this whole structure may have

188 been mobilized and inserted between the nt 1,049 and nt 1,050 of a DNA methyl transferase  
189 gene located on an IncA/C<sub>2</sub> plasmid backbone (Figure 3F). The resulting resistance plasmid is  
190 at the end one of those responsible for the spread of *mcr* genes among Enterobacteriaceae.

## 191 MATERIAL AND METHODS

192 **Bacterial isolate and susceptibility testing.** Screening of colistin-resistant isolates  
193 was performed from 126 different pigs in ten swine herds in different states of the state of  
194 Minas Gerais in Brazil, all pigs presenting post-weaning diarrhea. The isolates were initially  
195 tested for colistin resistance using agar dilution methods. All colonies growing on plates  
196 supplemented with >2µg/ml of colistin were confirmed by the commercialized Rapid  
197 Polymyxin NP test (ELITech Microbiology, France) (30) and minimal inhibitory  
198 concentrations (MICs) were determined by broth microdilution method using cation-adjusted  
199 MH broth. Antimicrobial susceptibility testing for other antibiotics families was performed  
200 according to the standard disk diffusion method on Mueller-Hinton (MH) agar plates  
201 following the CLSI recommendations (31).

202 **WGS and molecular analysis.** PCR screening for *mcr* genes was performed using  
203 primers designed to detect all known variants of MCR-3. Primers MCR-3allF (5'-GCA TTT  
204 ATG CTG AAC TGG CG-3') and MCR-3allR (5'-AGC GGC TTT CTG CTG CAA AC -3')

205 were used, and corresponding amplicons were subsequently sequenced (Microsynth, Balgach,  
206 Switzerland). Whole genomic DNA of the MCR-3-positive isolate was extracted with the  
207 Sigma-Aldrich GenElute™ Bacterial Genomic DNA Kit. Genomic libraries were assessed  
208 using the NexteraXT library preparation kit (Illumina Inc., San Diego, CA) and sequencing  
209 was performed using the Illumina MiniSeq system with 300-bp paired-end reads and a  
210 coverage of 50X. Generated FastQ data were compiled and analyzed using the CLC genomic  
211 workbench 7.5.1 (CLC bio, Aarhus, Denmark). Reads were de novo assembled with  
212 automatic bubble and word size and contigs were generated using the mapping mode “map  
213 reads back to contigs” with a minimum contig length of 800 nucleotides.

214 The resulting contigs were uploaded into the Center for Genomic Epidemiology server  
215 (<http://www.genomicepidemiology.org/>). Plasmid replicon typing, multilocus sequence  
216 typing, serotype and antimicrobial resistance determinants were determined using  
217 PlasmidFinder 1.3, MLST 1.8, SerotypeFinder 1.1 and ResFinder 3.0, respectively (32-34).  
218 Phylogroup analysis was performed by using the Clermont method (35). Sequence  
219 alignments and construction of phylogenetic trees were performed with the Seaview  
220 alignment tool version 4 (Prabi, La Doua, Lyon, France) (36).

221 Plasmid analysis was performed using Kieser extraction method (37) followed by gel  
222 electrophoresis in order to estimate the size of the plasmid containing the *mcr-3* gene using  
223 the *E. coli* strain 50192 harboring four plasmids of 154, 66, 48 and 7 kb, respectively, as  
224 plasmid size marker. The determination of the incompatibility group was confirmed by PCR-  
225 based replicon typing (PBRT) (38).

226 Conjugation experiments were performed using the azide-resistant *E. coli* J53 strain. In  
227 addition, conjugation were also performed in the temocillin-resistant *Pseudomonas*  
228 *aeruginosa* PAO1, in the azide-resistant *Klebsiella pneumoniae* CIP53153 and in the azide-  
229 resistant *Aeromonas punctate* CIP102629 recipient strains to test the broad host range of the  
230 plasmid coding for the *mcr-3.12* variant. Both donor and recipient strains were cultured in  
231 exponential phase, then mixed on solid LB agar using filters at a 1:10 donor:recipient ratio.  
232 After 5 h of incubation, filters were resuspended in NaCl 0.85% and bacterial mixture were  
233 plated onto agar plates supplemented with colistin (1 µg/ml) and sodium azide (100 µg/ml)  
234 for *E. coli* or with temocillin (50 µg/ml) and sodium azide (100 µg/ml) for *P. aeruginosa*.  
235 Since the plasmid bearing the *mcr-3.12* gene conferred resistance to tetracycline, conjugations  
236 using *K. pneumoniae* and *A. punctata* as recipients were attempted using tetracycline (100  
237 µg/ml) and sodium azide (100 µg/ml) as selective molecules. Susceptibility of all

238 transconjugants to antibiotics was confirmed by antibiogram followed by PCR for the *mcr-3*-  
239 like gene.

240       **Analysis of the LPS modification.** The LPS of *E. coli* J53 (unmodified lipid A),  
241 TCAf24 (*J53-mcr-1* transconjugant) and I112 (MCR-3-like producers) were analyzed by mass  
242 spectrometry (MS). The lipid A was obtained by the hydrolysis of 3 mg of lyophilized  
243 bacteria in 120  $\mu$ l of isobutyric acid and 1 M ammonium hydroxide (5:3; v:v), heated for 1 h  
244 at 100°C and cooled at 4°C before centrifugation, as previously described (39). The  
245 supernatant was then diluted with water and lyophilized before wash with methanol. The  
246 insoluble lipid A obtained was finally extracted in a chloroform:methanol:water (3:1:0.25,  
247 v:v:v) mixture. MALDI-MS analysis was performed using a PerSeptive Voyager STR (PE  
248 Biosystems, France) time-of-flight mass spectrometer in linear negative ion mode.  
249 Dihydroxybenzoic acid (DHB) at 10 mg/ml in 0.1 M citric acid in chloroform:methanol:water  
250 (3:1.5:0.25;v:v:v) was used as matrix.

251       **Cloning and overexpression of the *mcr-3.12* gene.** The new *mcr-3* variant was  
252 cloned into the arabinose-inducible pBAD<sub>6</sub> vector in order to determine the impact of the  
253 expression of the MCR-3-12 phosphoethanolamine transferase on colistin susceptibility.

254 Induction of pBAD<sub>b</sub> vector was performed using MH broth supplemented with L-arabinose  
255 1% as previously described (8).

256

257

#### ACKNOWLEDGMENTS

258 This work has been funded by the University of Fribourg, by the Swiss National Science  
259 Foundation (project FNS-407240\_177381), and by grants from the ANIWH A ERA-NET  
260 project, Switzerland, the OFSP, Bern, Switzerland (grant n°16009294), and the Novartis  
261 Foundation for medical-biological Research.

262

263



REFERENCES

- 264
- 265 1- **Poirel L, Jayol A, Nordmann P.** 2017. Polymyxins: antibacterial activity,  
266 susceptibility testing, and resistance mechanisms encoded by plasmids or  
267 chromosomes. *Clin Microbiol Rev* **30**:557–596.
- 268 2- **Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B,**  
269 **Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH,**  
270 **Shen J.** 2016. Emergence of plasmid-mediated colistin resistance mechanism MCR-1  
271 in animals and human beings in China: a microbiological and molecular biological  
272 study. *Lancet Infect Dis* **16**:161-168.
- 273 3- **Xavier BB, Lammens C, Ruhel R, Kumar-Singh S, Butaye P, Goossens H,**  
274 **Malhotra-Kumar S.** 2016. Identification of a novel plasmid-mediated colistin-  
275 resistance gene, *mcr-2*, in *Escherichia coli*, Belgium, June 2016. *Euro Surveill* **21**.
- 276 4- **Yin W, Li H, Shen Y, Liu Z, Wang S, Shen Z, Zhang R, Walsh TR, Shen J, Wang**  
277 **Y.** 2017. Novel plasmid-mediated colistin resistance gene *mcr-3* in *Escherichia coli*.  
278 *MBio* **8**.
- 279 5- **Carattoli A, Villa L, Feudi C, Curcio L, Orsini S, Luppi A, Pezzotti G, Magistrali**  
280 **CF.** 2017. Novel plasmid-mediated colistin resistance *mcr-4* gene in *Salmonella* and  
281 *Escherichia coli*, Italy 2013, Spain and Belgium, 2015 to 2016. *Euro Surveill* **3**:2231.

- 282 **6- Borowiak M, Fischer J, Hammerl JA, Hendriksen RS, Szabo I, Malorny B.** 2017.  
283 Identification of a novel transposon-associated phosphoethanolamine transferase gene,  
284 *mcr-5*, conferring colistin resistance in d-tartrate fermenting *Salmonella enterica*  
285 *subsp. enterica* serovar Paratyphi B. J Antimicrob Chemother **72**:3317-3324.
- 286 **7- Sun J, Xu Y, Gao R, Lin J, Wei W, Srinivas S, Li D, Yang RS, Li XP, Liao XP,**  
287 **Liu YH, Feng Y.** 2017. Deciphering MCR-2 colistin resistance. MBio **8**(3).
- 288 **8- Kieffer N, Nordmann P, Poirel L.** 2017. *Moraxella* species as potential sources of  
289 MCR-like polymyxin resistance determinants. Antimicrob. Agents Chemother  
290 **61**:e00129-17.
- 291 **9- Poirel L, Kieffer N, Fernandez-Garayzabal JF, Vela AI, Larpin Y, Nordmann P.**  
292 2017. MCR-2-mediated plasmid-borne polymyxin resistance most likely originates  
293 from *Moraxella pluranimalium*. J Antimicrob Chemother **72**:2947-2949.
- 294 **10- Litrup E, Kiil K, Hammerum AM, Roer L, Nielsen EM, Torpdahl M.** 2017.  
295 Plasmid-borne colistin resistance gene *mcr-3* in *Salmonella* isolates from human  
296 infections, Denmark, 2009-17. Euro Surveill **03**;22.
- 297 **11- Hernández M, Iglesias MR, Rodríguez-Lázaro D, Gallardo A, Quijada N,**  
298 **Miguela-Villoldo P, Campos MJ, Píriz S, López-Orozco G, de Frutos C, Sáez JL,**

- 299            **Ugarte-Ruiz M, Domínguez L, Quesada A.** 2017. Co-occurrence of colistin-  
300            resistance genes *mcr-1* and *mcr-3* among multidrug-resistant *Escherichia coli* isolated  
301            from cattle, Spain, September 2015. Euro Surveill **03**;22.
- 302            **12- Liu L, Feng Y, Zhang X, McNally A, Zong Z.** 2017. New variant of *mcr-3* in an  
303            extensively drug-resistant *Escherichia coli* clinical isolate carrying *mcr-1* and *bla*<sub>NDM</sub>-  
304            5. Antimicrob Agents Chemother **61**:e01757-17.
- 305            **13- Ling Z, Yin W, Li H, Zhang Q, Wang X, Wang Z, Ke Y, Wang Y, Shen J.** 2017.  
306            Chromosome-mediated *mcr-3* variants in *Aeromonas veronii* from chicken meat.  
307            Antimicrob Agents Chemother **61**:e01272-17.
- 308            **14- Eichhorn I, Feudi C, Wang Y, Kaspar H, Feßler AT, Lübke-Becker A, Michael**  
309            **GB, Shen J, Schwarz S.** 2018. Identification of novel variants of the colistin  
310            resistance gene *mcr-3* in *Aeromonas* spp. from the national resistance monitoring  
311            programme GERM-Vet and from diagnostic submissions. J Antimicrob Chemother; in  
312            press.
- 313            **15- Wang X, Zhai W, Li J, Liu D, Zhang Q, Shen Z, Wang S, Wang Y.** 2018. Presence  
314            of an *mcr-3* variant in *Aeromonas caviae*, *Proteus mirabilis*, and *Escherichia coli* from  
315            one domestic duck. Antimicrob Agents Chemother **62**:e02106-17.

- 316 **16- Liu YY, Chandler CE, Leung LM, McElheny CL, Mettus RT, Shanks RMQ, Liu**  
317 **JH, Goodlett DR, Ernst RK, Doi Y.** 2017. Structural modification of  
318 lipopolysaccharide conferred by *mcr-1* in Gram-Negative ESKAPE pathogens.  
319 Antimicrob Agents Chemother **61**:e00580-17.
- 320 **17- Kieffer N, Aires-de-Sousa M, Nordmann P, Poirel L.** 2017. High rate of MCR-1-  
321 producing *Escherichia coli* and *Klebsiella pneumoniae* among pigs, Portugal. Emerg  
322 Infect Dis **23**:2023-2029.
- 323 **18- Rau RB, de Lima-Morales D, Wink PL, Ribeiro AR, Martins AF, Barth AL.**  
324 2018. Emergence of *mcr-1* producing *Salmonella enterica* serovar Typhimurium from  
325 retail meat: first detection in Brazil. Foodborne Pathog Dis **15**:58-59.
- 326 **19- Monte DF, Mem A, Fernandes MR, Cerdeira L, Esposito F, Galvão JA, Franco**  
327 **BDGM, Lincopan N, Landgraf M.** 2017. Chicken meat as a reservoir of colistin-  
328 resistant *Escherichia coli* strains carrying *mcr-1* genes in South America. Antimicrob  
329 Agents Chemother **61**:e02718-16.
- 330 **20- Sellera FP, Fernandes MR, Sartori L, Carvalho MP, Esposito F, Nascimento CL,**  
331 **Dutra GH, Mamizuka EM, Pérez-Chaparro PJ, McCulloch JA, Lincopan N.**  
332 2017. *Escherichia coli* carrying IncX4 plasmid-mediated *mcr-1* and *bla<sub>CTX-M</sub>* genes in

333 infected migratory Magellanic penguins (*Spheniscus magellanicus*). J Antimicrob  
334 Chemother **72**:1255-1256.

335 **21-Fernandes MR, Sellera FP, Esposito F, Sabino CP, Cerdeira L, Lincopan N.**  
336 2017. Colistin-resistant *mcr-1*-positive *Escherichia coli* on public beaches, an  
337 infectious threat emerging in recreational waters. Antimicrob Agents Chemother  
338 **61**:e00234-17.

339 **22-Rossi F, Girardello R, Morais C, Cury AP, Martins LF, da Silva AM, Abdala E,**  
340 **Setubal JC, da Silva Duarte AJ.** 2017. Plasmid-mediated *mcr-1* in carbapenem-  
341 susceptible *Escherichia coli* ST156 causing a blood infection: an unnoticeable spread  
342 of colistin resistance in Brazil? Clinics (Sao Paulo) **72**:642-644.

343 **23-Rocha IV, Andrade CADN, Campos TL, Rezende AM, Leal NC, Vidal CFL,**  
344 **Xavier DE.** 2017. Ciprofloxacin-resistant and extended-spectrum  $\beta$ -lactamase-  
345 producing *Escherichia coli* ST410 strain carrying the *mcr-1* gene associated with  
346 bloodstream infection. Int J Antimicrob Agents **49**:655-656.

347 **24-Conceição-Neto OC, Aires CAM, Pereira NF, da Silva LHJ, Picão RC, Siqueira**  
348 **BN, Albano RM, Asensi MD, Carvalho-Assef APD.** 2017. Detection of the plasmid-

- 349 mediated *mcr-1* gene in clinical KPC-2-producing *Escherichia coli* isolates in Brazil.  
350 Int J Antimicrob Agents **50**:282-284.
- 351 **25- Aires CAM, da Conceição-Neto OC, Tavares E Oliveira TR, Dias CF, Montezzi**  
352 **LF, Picão RC, Albano RM, Asensi MD, Carvalho-Assef APD.** 2017. Emergence of  
353 the plasmid-mediated *mcr-1* gene in clinical KPC-2-producing *Klebsiella pneumoniae*  
354 Sequence Type 392 in Brazil. Antimicrob Agents Chemother **61**(7).
- 355 **26- Dalmolin TV, Martins AF, Zavascki AP, de Lima-Morales D, Barth AL.** 2018.  
356 Acquisition of the *mcr-1* gene by a high-risk clone of KPC-2-producing *Klebsiella*  
357 *pneumoniae* ST437/CC258, Brazil. Diagn Microbiol Infect Dis **90**:132-133.
- 358 **27- Esposito F, Fernandes MR, Lopes R, Muñoz M, Sabino CP, Cunha MP, Silva**  
359 **KC, Cayô R, Martins WMBS, Moreno AM, Knöbl T, Gales AC, Lincopan N.**  
360 2017. Detection of colistin-resistant MCR-1-positive *Escherichia coli* by use of assays  
361 based on inhibition by EDTA and Zeta potential. J Clin Microbiol **55**:3454-3465.
- 362 **28- Pulss S, Semmler T, Prenger-Berninghoff E, Bauerfeind R, Ewers C.** 2017. First  
363 report of an *Escherichia coli* strain from swine carrying an OXA-181 carbapenemase  
364 and the colistin resistance determinant MCR-1. Int J Antimicrob Agents **50**:232-236.

- 365 **29-Poirel L, Lartigue MF, Decousser JW, Nordmann P.** 2005. ISEcp1B-mediated  
366 transposition of *bla*<sub>CTX-M</sub> in *Escherichia coli*. *Antimicrob Agents Chemother* **49**:447-  
367 450.
- 368 **30-Poirel L, Larpin Y, Dobias J, Stephan R, Decousser JW, Madec JY, Nordmann**  
369 **P.** 2018. Rapid Polymyxin NP test for the detection of polymyxin resistance mediated  
370 by the *mcr-1/mcr-2* genes. *Diagn Microbiol Infect Dis* **90**:7-10.
- 371 **31-Clinical and Laboratory Standards Institute.** Performance standards for  
372 antimicrobial susceptibility testing; 26th informational supplement (M100–S26).  
373 Wayne (PA): The Institute; 2016.
- 374 **32-Joensen KG, Tetzschner AM, Iguchi A, Aarestrup FM, Scheutz F.** 2015. Rapid  
375 and easy in silico serotyping of *Escherichia coli* using whole genome sequencing  
376 (WGS) data. *J.Clin.Microbiol* **53**:2410-2426.
- 377 **33-Carattoli A, Zankari E, García-Fernández A, Voldby Larsen M, Lund O, Villa L,**  
378 **Møller Aarestrup F, Hasman H.** 2014. In silico detection and typing of plasmids  
379 using PlasmidFinder and plasmid multilocus sequence typing. *Antimicrob Agents*  
380 *Chemother* **58**:3895-3903.

- 381 **34-Zankari E, Hasman H, Cosentino S, Vestergaard M, Rasmussen S, Lund O,**  
382 **Aarestrup FM, Larsen MV.** 2012. Identification of acquired antimicrobial resistance  
383 genes. *J Antimicrob Chemother* **67**:2640-2644.
- 384 **35-Clermont O, Bonacorsi S, Bingen E.** 2000. Rapid and simple determination of the  
385 *Escherichia coli* phylogenetic group. *Appl Environ Microbiol* **66**:4555-4558.
- 386 **36-Gouy M, Guindon S, Gascuel O.** 2010. SeaView version 4: A multiplatform  
387 graphical user interface for sequence alignment and phylogenetic tree building. *Mol*  
388 *Biol Evol* **27**:221-224.
- 389 **37-Kieser T.** 1984. Factors affecting the isolation of CCC DNA from *Streptomyces*  
390 *lividans* and *Escherichia coli*. *Plasmid* **12**:19-36.
- 391 **38-Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ.** 2005.  
392 Identification of plasmids by PCR-based replicon typing. *J Microbiol Methods*  
393 **63**:219-228.
- 394 **39-Breton A, Novikov A, Martin R, Tissieres P, Caroff M.** 2017. Structural and  
395 biological characteristics of different forms of *V. filiformis* lipid A: use of MS to  
396 highlight structural discrepancies. *J Lipid Res* **58**:543-552.
- 397



398

### Figure Legends

399 Figure 1. Phylogenetic tree obtained for all the identified MCR-like enzymes including all  
400 MCR-3 variants by distance method using Neighbor-Joining algorithm (SeaView version 4  
401 software). Branch lengths are drawn to scale and are proportional to the number of amino  
402 acids substitutions with 500 bootstrap replications. The distance along the vertical axis has no  
403 significance. Percentage of amino acids identity shared between the MCR-3.12 variant and  
404 the other MCR-like enzymes is indicated in brackets.

405

406 Figure 2. Mass spectrometry analysis of lipid A from strain *E. coli* J53 (A), its transconjugant  
407 carrying the *mcr-1* gene (B) and the clinical isolate I112 expressing the *mcr-3.12* gene (C).  
408 The addition of a PEtN group is indicated by a black arrow.

409

410 Figure 3. Proposed model of the chronology of the acquisition of the *mcr-3.12* gene into the  
411 IncA/C2 plasmid. The genes *eamA* and *dgkA* encode for a metabolite transporter and a  
412 diacylglycerol kinase, respectively. *intA* and *intB* represent putative integrases;  $\alpha$ ,  $\beta$  and  $\gamma$  are  
413 the ORF encoding for a reverse transcriptase, a transcriptional regulator and a diguanylate  
414 cyclase, respectively;  $\delta$  corresponds to the ORF encoding for a DNA methyltransferase  
415 located onto the IncA/C2 plasmid backbone.

416

417

418

BioNJ 511 sites Poisson 500 repl.





